PO.CH01.02 · 化学
MICRO-TAG®细胞靶点结合以功能相关性重新定义GPCR药物发现
MICRO-TAG® cell target engagement redefines GPCR drug discovery with functional relevance
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
G蛋白偶联受体(GPCR)构成了膜蛋白中最大且药理学上最重要的家族,可将细胞外信号转化为细胞内信号级联反应。作为细胞代谢、分化、生长、神经传递和感觉知觉的主要调控者,GPCR仍是最有价值但技术上最具挑战性的治疗靶点之一。发现靶向这些受体的药物是早期药物发现中的一大难题。依赖重组或纯化蛋白的传统生物物理方法收效有限,因为它们难以捕捉GPCR脱离其天然细胞环境后的结构和功能相关性。在此,我们提出MICRO-TAG®细胞靶点结合平台,作为一种细胞化的、可转化的检测系统,能够鉴定并功能性验证在天然膜环境中直接结合GPCR的化合物。以GPR75(一种与肥胖、癌症和代谢综合征相关的受体)为模型,我们展示了MICRO-TAG®的能力:(1)检测直接的配体-受体结合,(2)监测下游GPCR信号传导,以及(3)提供基于报告基因的、对激动剂或拮抗剂活性的灵敏读出。通过将直接靶点结合与细胞环境中的功能通路探查相结合,MICRO-TAG®为生物学中一些最具挑战性的药物靶点类别实现了可扩展且生理相关的药物发现。
查看英文原文 English abstract
G protein-coupled receptors (GPCRs) form the largest and most pharmacologically important family of membrane proteins, translating extracellular cues into intracellular signaling cascades. As master regulators of cell metabolism, differentiation, growth, neurotransmission, and sensory perception, GPCRs remain among the most valuable yet technically challenging therapeutic targets. Discovery of drugs targeting these receptors is a challenge in early drug discovery. Conventional biophysical methods that rely on recombinant or purified proteins have achieved limited success, as they poorly capture the structural and functional relevance of GPCRs outside of their native cellular context. Here, we present the MICRO-TAG ® Cell Target Engagement platform as a cellular and translatable assay system capable of identifying and functionally validating compounds that directly bind GPCRs in their native membrane environment. Using GPR75 - a receptor implicated in obesity, cancer, and metabolic syndrome-as a model, we demonstrate the ability of MICRO-TAG ® to: (1) detect direct ligand-receptor binding, (2) monitor downstream GPCR signaling, and (3) provide sensitive reporter-based readouts of agonist or antagonist activity. By integrating direct target engagement with functional pathway interrogation in a cellular environment, MICRO-TAG ® enables scalable and physiologically relevant drug discovery for some of the most challenging drug target classes in biology.
利益披露 Disclosure
I. Babic, None.